UFRGS

Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs R&D Partnership Agreement for Development of GLP1 Supplement for Pets

Retrieved on: 
Wednesday, November 8, 2023
Faculty, NYSE, São Paulo, Federal University of Rio Grande do Sul, Obesity, Cat, Université de Montréal Faculty of Veterinary Medicine, Pet, Doctor of Philosophy, Rio, UNESP, APH, Veterinary medicine, MOU, Medical school, Faculty of Medicine, University of Colombo, University of São Paulo, UFRGS, Animal, University, Universidad, Overweight, Better Choice Parking, Pain management, GLP1, Dog, MS, Physiology, Medicine, Pharmacology, Anesthesia

TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.

Key Points: 
  • TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.
  • The MOU sets out the basis for Dr. Crosignani to commence research and development of a GLP1 supplement for use in companion animals.
  • In addition, Dr. Crosignani has a post-doctorate degree from UNESP, Faculty of Medicine, researching in the field of pain management.
  • We see the use of the GLP1 supplement as a significant opportunity for the pet health industry and are assembling top tier partners to help Better Choice and our brands, including Halo, become pioneers in this sector,” commented Mike Young, Chairman of the Board for Better Choice.

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

Retrieved on: 
Wednesday, February 9, 2022
Immunosuppression, Growth, MPS II, Glycosaminoglycan, MPS, HS, Week, Conversation, U.S. Securities and Exchange Commission, Safety, Tissue, SEC, Financial condition report, Risk, AAV, Disease, Food, Organ dysfunction, Cell, Drug Quality and Security Act, Department, Securities Act of 1933, IDS, Cerebrospinal fluid, Intention, Perception, II, Microdeletion syndrome, Șaeș, Central nervous system, Biomarker, Traffic barrier, SD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ERT, Cohort, Acquisition, Urine, Technology, CNS, UFRGS, Patient, CGMP, Securities Exchange Act of 1934, Hunter syndrome, Department of Genetics, University of Cambridge, COVID-19, Result, Plasma, Analysis, CSF, Annual report, Caregiver, Cognition, Nasdaq, GAG, Serum, Pharmaceutical industry, Medical imaging, Vaccine, I2S

"We are pleased to share additional data from patients in Cohorts 1-3 of our RGX-121 Phase I/II trial," said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO.

Key Points: 
  • "We are pleased to share additional data from patients in Cohorts 1-3 of our RGX-121 Phase I/II trial," said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO.
  • "The data presented today continues to support the early positive signals seen in the emerging clinical profile of RGX-121 for the treatment of MPS II.
  • I am encouraged by the biomarker activity and impact on neurodevelopmental improvements observed in this trial, and I look forward to additional updates."
  • RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector.